Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

May 31, 2015

Conditions
Age Related Macular Degeneration
Interventions
DRUG

Subretinally injected RetinoStat

Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.

Trial Locations (3)

97239

Dr Andreas Lauer - Oregon Health & Science University, Portland

52242-1098

The University of Iowa, Iowa City

21287-9277

Johns Hopkins University Hospital, Baltimore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oxford BioMedica

INDUSTRY